Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 13Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Neoplasms 4Lung Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 2Skin Neoplasms 2Skin Diseases 2Pancreatic Neoplasms 2Hematologic Neoplasms 2Uveal Melanoma 1Spinocerebellar Degenerations 1Solid Tumors Harboring a BRAF V600 Mutation 1Soft Tissue Neoplasms 1Peripheral Nervous System Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 5 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Multiple Myeloma 1Lymphoma 1Lymphatic Metastasis 1Low-grade Serous Ovarian Cancer 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1

Interventions

Alpelisib 4berzosertib 3Fulvestrant 3Everolimus 3parsaclisib 2Topotecan 2NVP-BKM120 2Cetuximab 2talazoparib 1sotorasib 1serabelisib 1ruxolitinib 1duvelisib 1dapagliflozin 1cobimetinib 1ceralasertib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1Paclitaxel 1Oxaliplatin 1Leuprolide 1Leucovorin 1Letrozole 1Irinotecan 1Goserelin 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hereditary Sensory and Autonomic Neuropathies × binimetinib × Clear all
NCT01320085 2024-01-24

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Pfizer

Phase 2 Completed
183 enrolled 35 charts
Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡